Notes from today’s concall.
FY22Q2
- Confident of growing sales at 15-20% for the remainder of FY22
- US customer base has increased by 20-25% over last year
- Part of growth is due to competitors’ inability to provide the product
- Sharda also supplies to MNCs where the margins are much better (very small percentage now)
- H1FY22 impairment: 4.4 cr.
- R&D is also outsourced
- Company cannot do buyback because of very high promoter shareholding
Disclosure: Invested (position size here).